Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016620 · ClinicalTrials.gov registry record
Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia
A clinical trial of Benign Prostatic Hyperplasia (BPH), sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT07016620 is a study of Benign Prostatic Hyperplasia (BPH) that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 20 participants, below the 107-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07016620, a study of Benign Prostatic Hyperplasia (BPH), is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Benign prostatic hyperplasia (BPH) is a common condition affecting aging men, often leading to lower urinary tract symptoms (LUTS). While Minimally Invasive Surgical Therapies (MIST) procedures offer less invasive alternatives to traditional surgery, some patients experience symptom recurrence or require further intervention due to lack of adequate relief of obstruction. Treatment of persistent obstruction after MIST therapy (BPH salvage therapy) typically requires surgical intervention like transurethral resection of prostate (TURP). This study proposes to evaluate the effectiveness of in-office transperineal laser ablation (TPLA) using the Echolaser system as a minimally invasive treatment option for these patients, potentially avoiding more invasive surgical procedures. The Cleveland Clinic sees a high volume of BPH salvage patients, making this an ideal setting for this research.
Conditions Studied
Interventions
- PROCEDURE Transperineal Laser Ablation (TPLA)
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-01-12 |
| Est. Completion | 2027-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07016620
The ClinicalTrials.gov registry entry for NCT07016620 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 3 other Benign Prostatic Hyperplasia (BPH) trials with a reported enrollment target (81% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Benign Prostatic Hyperplasia (BPH) appearing as the primary indexed condition, and to 1 intervention - of which Transperineal Laser Ablation (TPLA) is the first listed.
NCT07016620 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07016620 about?
NCT07016620 is a clinical study titled "Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia". Benign prostatic hyperplasia (BPH) is a common condition affecting aging men, often leading to lower urinary tract symptoms (LUTS). While Minimally Invasive Surgical Therapies (MIST) procedures offer less invasive alternatives to traditional surgery, some patients experience symptom recurrence or re...
What is the current status of trial NCT07016620?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2026-01-12. Estimated completion is 2027-09-01.
What conditions does trial NCT07016620 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia (BPH).
What interventions are being tested in trial NCT07016620?
The interventions under investigation include: Transperineal Laser Ablation (TPLA) (PROCEDURE).
Who is sponsoring clinical trial NCT07016620?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07016620 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia (BPH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.